Large-cohort screening projects in seven regions of China demonstrate the efficacy of extended HPV genotyping in triaging HPV-positive women - Scorecard - MDSpire
Clinical Scorecard: Extensive screening initiatives across seven regions in China highlight the effectiveness of advanced HPV genotyping for managing HPV-positive women.
At a Glance
Category
Detail
Condition
High-risk human papillomavirus infection and cervical precancer
Key Mechanisms
HPV DNA testing for primary screening and extended high-risk HPV genotyping for risk-based triage.
Target Population
Women aged 25–64 undergoing cervical cancer screening, with triage analyses focused on HPV-positive women.
Care Setting
Population-based cervical cancer screening programs.
Key Highlights
The World Health Organization recommends HPV DNA testing as a screening modality for cervical cancer prevention.
Primary HPV screening has higher clinical sensitivity and negative predictive value but slightly lower specificity than conventional cytology.
Extended high-risk HPV genotyping offers a standardized and reproducible approach to risk stratification.
Cytological evaluation cannot be performed on self-collected cervical specimens, limiting its use in self-sampling programs.
HPV-16 single infection had the highest CIN3+ rate; HPV-31, HPV-33, HPV-52, and HPV-58 also warrant attention in triage algorithms.
Guideline-Based Recommendations
Diagnosis
Confirm cervical lesions through biopsy-based pathological diagnosis following standardized colposcopy-directed and random biopsy protocols.
Management
Extended genotype panels may provide a cytology-free triage option for HPV-positive women while maintaining high sensitivity for CIN3+ detection.
Monitoring & Follow-up
Long-term follow-up is needed to determine whether extended genotyping reduces the burden of invasive cervical cancer.
Risks
Consider genotype-specific CIN3+ risks when triaging HPV-positive women, with particular attention to HPV-16, HPV-31, HPV-33, HPV-52, and HPV-58.
Patient & Prescribing Data
The triage analysis included 7,821 HPV-positive women with complete HPV testing, cytology, and pathological data. The study evaluated screening strategies rather than a medication and therefore provided no prescribing data. Extended genotyping produced a modest increase in colposcopy referrals compared with standard triage.
Clinical Best Practices
Use standardized and reproducible molecular methods for extended HPV genotyping.
Apply consistent pathological diagnostic standards and CIN3+ endpoint definitions.
Balance high CIN3+ sensitivity against the modest increase in colposcopy referrals associated with extended genotype panels.
Related Resources & Content
Study: “Large-cohort screening projects in seven regions of China demonstrate the efficacy of extended HPV genotyping in triaging HPV-positive women” — Wenkui Dai, Yu Liu, Hui Du, Chunlei Guo, Di Wu, Xin Jiang, Shuai Cheng Li, Changzhong Li, Xinfeng Qu, and Ruifang Wu; International Journal of Infectious Diseases, Volume 171 (2026), article 109077; accepted August 23, 2026.
